Fig. 2
2d-aDCs induce expansion and activation of CD8+ NY-ESO1 and HER2-specific T cells in a breast cancer patient after anti-TTx. a. Percentage of TEMRA HER2/neu-specific CD8+ T cells subsequent to induction of in situ 2d-aDCs or 2d-stDCs in total PBMCs (MCC-002) induced for 6 days comparing samples obtained before (left column) and after anti-TTx (right column) pulsed with HER2/neu369–377 peptide. b. Percentage of TEMRA NY-ESO 1-specific CD8+ T cells from patient MCC-002 derived from naïve CD8+ T cells in co-culture with 2d-aDCs or 2d-stDCs-pulsed/unpulsed with NY-ESO 1157–165 and stimulated with DCs for 14 days and boosted with corresponding DCs for 6 additional days, comparing samples obtained before (left column) and after anti-TTx (right column). X: not done. Results of experiments presented in panels a and b are representative of two performed